title: Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells.
abstract: Gliomas are highly resistant to conventional treatment. Improved knowledge of the molecular defects of glioma cells offers new avenues for the development of gene therapy strategies. Transfer of the p53 gene has proven effective in suppressing proliferation in human glioma cell lines. However, several human glioma cell lines are resistant to p53-induced cell death. The E2F family of transcription factors are pivotal for the regulation of cell-cycle and cell-death related genes in gliomas. In the present study, we sought a more effective strategy for glioma treatment by examining the therapeutic potential of the simultaneous transfer of p53 and E2F-2 to gliomas. Trypan blue cell viability assays and flow cytometric cell-cycle analysis demonstrated that the transfer of both p53 and E2F-2 induced cell death in D-54 MG, a p53-resistant glioma cell line. In addition, transfer of E2F-2 did not interfere with the apoptotic properties of exogenous wild-type p53 in U-251 MG cells. Finally, the expression of E2F-2 in D-54 MG cells suppressed the expression of the apoptotic molecule mdm-2 induced by exogenous p53 in these cells. These results show that co-expression of E2F-2 and p53 enhances the anti-cancer effect of p53 in gliomas.
authors.affiliation: Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: P G
authors.initials: PG
authors.lastname: Mitlianga
authors.forename: A P
authors.initials: AP
authors.lastname: Kyritsis
authors.forename: C
authors.initials: C
authors.lastname: Gomez-Manzano
authors.forename: M G
authors.initials: MG
authors.lastname: Lemoine
authors.forename: M
authors.initials: M
authors.lastname: Hu
authors.forename: T J
authors.initials: TJ
authors.lastname: Liu
authors.forename: W K
authors.initials: WK
authors.lastname: Yung
authors.forename: J
authors.initials: J
authors.lastname: Fueyo
mesh_terms: D000199:Actins / Q000378:metabolism; D000256:Adenoviridae; D017209:Apoptosis / Q000502:physiology*; D050703:E2F2 Transcription Factor; D016158:Genes, p53 / Q000502:physiology*; D005909:Glioblastoma / Q000378:metabolism* / Q000628:therapy; D005910:Glioma / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051736:Proto-Oncogene Proteins c-mdm2; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000378:metabolism
chemical_list: D000199:Actins; D050703:E2F2 Transcription Factor; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D014157:Transcription Factors; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2